Subscribe to RSS
DOI: 10.1055/s-2007-984741
Neuroendocrine Effects of Androgens in Adult Polycystic Ovary Syndrome and Female Puberty
Publication History
Publication Date:
20 August 2007 (online)
ABSTRACT
In addition to hyperandrogenism and ovulatory dysfunction, polycystic ovary syndrome (PCOS) is characterized by neuroendocrine abnormalities including a persistently rapid gonadotropin-releasing hormone (GnRH) pulse frequency. Rapid GnRH pulsatility favors pituitary secretion of luteinizing hormone (LH) over that of follicle-stimulating hormone (FSH). Excess LH stimulates ovarian androgen production, whereas relative deficits in FSH impair follicular development. The rapid GnRH pulse frequency is a result of reduced progesterone-mediated feedback inhibition of the GnRH pulse generator secondary to infrequent luteal phase increases in progesterone, as well as reduced hypothalamic sensitivity to progesterone feedback. Progesterone sensitivity is restored by treatment with the androgen receptor blocker flutamide. As such, hyperandrogenemia appears to play an important pathophysiologic role in PCOS. Adolescent hyperandrogenemia is believed to be a precursor to adult PCOS. In addition to increased LH concentrations and pulse frequency, some girls with elevated androgen levels also demonstrate reduced hypothalamic sensitivity to progesterone feedback. We hypothesize that excess peripubertal androgens may reduce the sensitivity of the GnRH pulse generator to sex steroid inhibition in susceptible individuals, resulting in increased GnRH pulse frequency and subsequent abnormalities in gonadotropin secretion, ovarian androgen production, and ovulatory function. Over time, these abnormalities may progress to the clinical hyperandrogenism and chronic oligo-ovulation typical of adult PCOS.
KEYWORDS
Polycystic ovary syndrome - puberty - androgens - gonadotropin-releasing hormone (GnRH) - gonadotropins
REFERENCES
- 1 Azziz R, Woods K S, Reyna R et al.. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004; 89(6) 2745-2749
-
2 Zawadski J, Dunaif A.
Diagnostic criteria for polycystic ovary syndrome: towards a rational approach . In: Dunaif A, Givens J, Haseltine F, Merriam G Polycystic Ovary Syndrome. Oxford, United Kingdom; Blackwell Scientific 1992: 377-384 - 3 Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997; 18(6) 774-800
- 4 Legro R S, Kunselman A R, Dodson W C, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab. 1999; 84(1) 165-169
- 5 Apridonidze T, Essah P A, Iuorno M J, Nestler J E. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005; 90(4) 1929-1935
- 6 Sam S, Legro R S, Bentley-Lewis R, Dunaif A. Dyslipidemia and metabolic syndrome in the sisters of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005; 90(8) 4797-4802
- 7 Nelson V L, Legro R S, Strauss III J F, McAllister J M. Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries. Mol Endocrinol. 1999; 13(6) 946-957
- 8 Ehrmann D A, Barnes R B, Rosenfield R L. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. Endocr Rev. 1995; 16(3) 322-353
- 9 Gilling-Smith C, Story H, Rogers V, Franks S. Evidence for a primary abnormality of thecal cell steroidogenesis in the polycystic ovary syndrome. Clin Endocrinol (Oxf). 1997; 47(1) 93-99
- 10 McCartney C R, Bellows A B, Gingrich M B et al.. Exaggerated 17-hydroxyprogesterone response to intravenous infusions of recombinant human LH in women with polycystic ovary syndrome. Am J Physiol Endocrinol Metab. 2004; 286(6) E902-E908
- 11 DeUgarte C M, Bartolucci A A, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril. 2005; 83(5) 1454-1460
- 12 Baillargeon J P, Jakubowicz D J, Iuorno M J, Jakubowicz S, Nestler J E. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil Steril. 2004; 82(4) 893-902
- 13 Nestler J E, Jakubowicz D J, de Vargas A F et al.. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab. 1998; 83(6) 2001-2005
- 14 Rebar R, Judd H L, Yen S S et al.. Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome. J Clin Invest. 1976; 57(5) 1320-1329
- 15 Waldstreicher J, Santoro N F, Hall J E, Filicori M, Crowley Jr W F. Hyperfunction of the hypothalamic-pituitary axis in women with polycystic ovarian disease: indirect evidence for partial gonadotroph desensitization. J Clin Endocrinol Metab. 1988; 66(1) 165-172
- 16 Taylor A E, McCourt B, Martin K A et al.. Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1997; 82(7) 2248-2256
- 17 Hayes F J, Taylor A E, Martin K A, Hall J E. Use of a gonadotropin-releasing hormone antagonist as a physiologic probe in polycystic ovary syndrome: assessment of neuroendocrine and androgen dynamics. J Clin Endocrinol Metab. 1998; 83(7) 2343-2349
- 18 Chang R J, Laufer L R, Meldrum D R et al.. Steroid secretion in polycystic ovarian disease after ovarian suppression by a long-acting gonadotropin-releasing hormone agonist. J Clin Endocrinol Metab. 1983; 56(5) 897-903
- 19 Steingold K, De Ziegler D, Cedars M et al.. Clinical and hormonal effects of chronic gonadotropin-releasing hormone agonist treatment in polycystic ovarian disease. J Clin Endocrinol Metab. 1987; 65(4) 773-778
- 20 Rasmussen D D, Gambacciani M, Swartz W, Tueros V S, Yen S S. Pulsatile gonadotropin-releasing hormone release from the human mediobasal hypothalamus in vitro: opiate receptor-mediated suppression. Neuroendocrinology. 1989; 49(2) 150-156
- 21 Filicori M, Santoro N, Merriam G R, Crowley Jr W F. Characterization of the physiological pattern of episodic gonadotropin secretion throughout the human menstrual cycle. J Clin Endocrinol Metab. 1986; 62(6) 1136-1144
- 22 Rossmanith W G, Liu C H, Laughlin G A et al.. Relative changes in LH pulsatility during the menstrual cycle: using data from hypogonadal women as a reference point. Clin Endocrinol (Oxf). 1990; 32(5) 647-660
- 23 Gill S, Lavoie H B, Bo-Abbas Y, Hall J E. Negative feedback effects of gonadal steroids are preserved with aging in postmenopausal women. J Clin Endocrinol Metab. 2002; 87(5) 2297-2302
- 24 Soules M R, Steiner R A, Clifton D K et al.. Progesterone modulation of pulsatile luteinizing hormone secretion in normal women. J Clin Endocrinol Metab. 1984; 58(2) 378-383
- 25 Nippoldt T B, Reame N E, Kelch R P, Marshall J C. The roles of estradiol and progesterone in decreasing luteinizing hormone pulse frequency in the luteal phase of the menstrual cycle. J Clin Endocrinol Metab. 1989; 69(1) 67-76
- 26 Romano G J, Krust A, Pfaff D W. Expression and estrogen regulation of progesterone receptor mRNA in neurons of the mediobasal hypothalamus: an in situ hybridization study. Mol Endocrinol. 1989; 3(8) 1295-1300
- 27 Clayton R N, Royston J P, Chapman J et al.. Is changing hypothalamic activity important for control of ovulation?. Br Med J (Clin Res Ed). 1987; 295(6589) 7-12
- 28 Daniels T L, Berga S L. Resistance of gonadotropin releasing hormone drive to sex steroid-induced suppression in hyperandrogenic anovulation. J Clin Endocrinol Metab. 1997; 82(12) 4179-4183
- 29 Pastor C L, Griffin-Korf M L, Aloi J A, Evans W S, Marshall J C. Polycystic ovary syndrome: evidence for reduced sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. J Clin Endocrinol Metab. 1998; 83(2) 582-590
- 30 Melrose P, Gross L. Steroid effects on the secretory modalities of gonadotropin-releasing hormone release. Endocrinology. 1987; 121(1) 190-199
- 31 Dunaif A. Do androgens directly regulate gonadotropin secretion in the polycystic ovary syndrome?. J Clin Endocrinol Metab. 1986; 63(1) 215-221
- 32 Sir-Petermann T, Rabenbauer B, Wildt L. The effect of flutamide on pulsatile gonadotrophin secretion in hyperandrogenaemic women. Hum Reprod. 1993; 8(11) 1807-1812
- 33 Eagleson C A, Gingrich M B, Pastor C L et al.. Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. J Clin Endocrinol Metab. 2000; 85(11) 4047-4052
- 34 Eagleson C A, Bellows A B, Hu K, Gingrich M B, Marshall J C. Obese patients with polycystic ovary syndrome: evidence that metformin does not restore sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by ovarian steroids. J Clin Endocrinol Metab. 2003; 88(11) 5158-5162
- 35 De Leo V, Lanzetta D, D'Antona D, la Marca A, Morgante G. Hormonal effects of flutamide in young women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1998; 83(1) 99-102
- 36 Dumesic D A, Abbott D H, Eisner J R, Goy R W. Prenatal exposure of female rhesus monkeys to testosterone propionate increases serum luteinizing hormone levels in adulthood. Fertil Steril. 1997; 67(1) 155-163
- 37 Robinson J E, Forsdike R A, Taylor J A. In utero exposure of female lambs to testosterone reduces the sensitivity of the gonadotropin-releasing hormone neuronal network to inhibition by progesterone. Endocrinology. 1999; 140(12) 5797-5805
- 38 Foecking E M, Szabo M, Schwartz N B, Levine J E. Neuroendocrine consequences of prenatal androgen exposure in the female rat: absence of luteinizing hormone surges, suppression of progesterone receptor gene expression, and acceleration of the gonadotropin-releasing hormone pulse generator. Biol Reprod. 2005; 72(6) 1475-1483
- 39 Sullivan S D, Moenter S M. Prenatal androgens alter GABAergic drive to gonadotropin-releasing hormone neurons: implications for a common fertility disorder. Proc Natl Acad Sci USA. 2004; 101(18) 7129-7134
- 40 Venturoli S, Porcu E, Fabbri R et al.. Postmenarchal evolution of endocrine pattern and ovarian aspects in adolescents with menstrual irregularities. Fertil Steril. 1987; 48(1) 78-85
- 41 Apter D, Vihko R. Endocrine determinants of fertility: serum androgen concentrations during follow-up of adolescents into the third decade of life. J Clin Endocrinol Metab. 1990; 71(4) 970-974
- 42 Ibanez L, Potau N, Francois I, de Zegher F. Precocious pubarche, hyperinsulinism, and ovarian hyperandrogenism in girls: relation to reduced fetal growth. J Clin Endocrinol Metab. 1998; 83(10) 3558-3562
- 43 Laitinen J, Taponen S, Martikainen H et al.. Body size from birth to adulthood as a predictor of self-reported polycystic ovary syndrome symptoms. Int J Obes Relat Metab Disord. 2003; 27(6) 710-715
- 44 Jaquet D, Leger J, Chevenne D, Czernichow P, Levy-Marchal C. Intrauterine growth retardation predisposes to insulin resistance but not to hyperandrogenism in young women. J Clin Endocrinol Metab. 1999; 84(11) 3945-3949
- 45 McCartney C R, Prendergast K A, Chhabra S et al.. The association of obesity and hyperandrogenemia during the pubertal transition in girls: obesity as a potential factor in the genesis of postpubertal hyperandrogenism. J Clin Endocrinol Metab. 2006; 91(5) 1714-1722
- 46 McCartney C R, Blank S K, Prendergast K A et al.. Obesity and sex steroid changes across puberty: evidence for marked hyperandrogenemia in pre- and early pubertal obese girls. J Clin Endocrinol Metab. 2007; 92 430-436
- 47 Reinehr T, de Sousa G, Roth C L, Andler W. Androgens before and after weight loss in obese children. J Clin Endocrinol Metab. 2005; 90(10) 5588-5595
- 48 Wabitsch M, Hauner H, Heinze E et al.. Body fat distribution and steroid hormone concentrations in obese adolescent girls before and after weight reduction. J Clin Endocrinol Metab. 1995; 80(12) 3469-3475
- 49 Ogden C L, Carroll M D, Curtin L R et al.. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA. 2006; 295(13) 1549-1555
- 50 Venturoli S, Porcu E, Fabbri R et al.. Longitudinal evaluation of the different gonadotropin pulsatile patterns in anovulatory cycles of young girls. J Clin Endocrinol Metab. 1992; 74(4) 836-841
- 51 Apter D, Butzow T, Laughlin G A, Yen S S. Accelerated 24-hour luteinizing hormone pulsatile activity in adolescent girls with ovarian hyperandrogenism: relevance to the developmental phase of polycystic ovarian syndrome. J Clin Endocrinol Metab. 1994; 79(1) 119-125
- 52 Wennink J M, Delemarre-van de Waal H A, Schoemaker R, Schoemaker H, Schoemaker J. Luteinizing hormone and follicle stimulating hormone secretion patterns in girls throughout puberty measured using highly sensitive immunoradiometric assays. Clin Endocrinol (Oxf). 1990; 33(3) 333-344
- 53 Boyar R, Finkelstein J, Roffwarg H et al.. Synchronization of augmented luteinizing hormone secretion with sleep during puberty. N Engl J Med. 1972; 287(12) 582-586
- 54 Chhabra S, McCartney C R, Yoo R Y et al.. Progesterone inhibition of the hypothalamic gonadotropin-releasing hormone pulse generator: evidence for varied effects in hyperandrogenemic adolescent girls. J Clin Endocrinol Metab. 2005; 90(5) 2810-2815
- 55 Cemeroglu A P, Foster C M, Warner R et al.. Comparison of the neuroendocrine control of pubertal maturation in girls and boys with spontaneous puberty and in hypogonadal girls. J Clin Endocrinol Metab. 1996; 81(12) 4352-4357
- 56 Apter D, Butzow T L, Laughlin G A, Yen S S. Gonadotropin-releasing hormone pulse generator activity during pubertal transition in girls: pulsatile and diurnal patterns of circulating gonadotropins. J Clin Endocrinol Metab. 1993; 76(4) 940-949
- 57 Norjavaara E, Ankarberg C, Albertsson-Wikland K. Diurnal rhythm of 17 beta-estradiol secretion throughout pubertal development in healthy girls: evaluation by a sensitive radioimmunoassay. J Clin Endocrinol Metab. 1996; 81(11) 4095-4102
- 58 Ankarberg C, Norjavaara E. Diurnal rhythm of testosterone secretion before and throughout puberty in healthy girls: correlation with 17beta-estradiol and dehydroepiandrosterone sulfate. J Clin Endocrinol Metab. 1999; 84(3) 975-984
- 59 Mitamura R, Yano K, Suzuki N et al.. Diurnal rhythms of luteinizing hormone, follicle-stimulating hormone, testosterone, and estradiol secretion before the onset of female puberty in short children. J Clin Endocrinol Metab. 2000; 85(3) 1074-1080
- 60 Cemeroglu A P, Kletter G B, Guo W et al.. In pubertal girls, naloxone fails to reverse the suppression of luteinizing hormone secretion by estradiol. J Clin Endocrinol Metab. 1998; 83(10) 3501-3506
- 61 Kletter G B, Foster C M, Brown M B et al.. Nocturnal naloxone fails to reverse the suppressive effects of testosterone infusion on luteinizing hormone secretion in pubertal boys. J Clin Endocrinol Metab. 1994; 79(4) 1147-1151
- 62 Kelch R P, Kaplan S L, Grumbach M M. Suppression of urinary and plasma follicle-stimulating hormone by exogenous estrogens in prepubertal and pubertal children. J Clin Invest. 1973; 52(5) 1122-1128
- 63 Rapisarda J J, Bergman K S, Steiner R A, Foster D L. Response to estradiol inhibition of tonic luteinizing hormone secretion decreases during the final stage of puberty in the rhesus monkey. Endocrinology. 1983; 112(4) 1172-1179
- 64 Wang Y. Is obesity associated with early sexual maturation? A comparison of the association in American boys versus girls. Pediatrics. 2002; 110(5) 903-910
Dr.
Susan K Blank
Center for Research in Reproduction, Box 800391
University of Virginia Health System, Charlottesville, VA 22908
Email: sek2h@virginia.edu